

Should MMR deficient tumours be treated differently?

- **1989 through 90's** 5-FU based chemotherapy standard of care after curative resection for Stage III colon cancer
- **1999** defective DNA MMR might be a mechanism for tumor resistance to 5-FU (Carethers et al)
- **2000 - 2001** population based studies MSI-H independent prognostic factor for survival (Gryfe et al; Samowitz et al)
- **2003** re-expression of silenced hypermethylated hMLH1 in MMR in CRC cells overcame resistance to 5-FU (Arnold et al)
- **2003** MSI-H CRC did not benefit from 5-FU based chemotherapy compared to MSI-L or MSS tumors (Ribic et al)
- **2005** review of 32 published studies MSI-H CRC better and suggestion of no benefit from adjuvant 5-FU (Popat et al)

Should MMR deficient tumours be treated differently?

- **Should patients with colon cancer and MSI-H receive adjuvant 5-FU based chemotherapy or should they be treated differently?**

Should MMR deficient tumours be treated differently?

